Juefeng Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juefeng Wan has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Zhen Zhang
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
20 shared publications - Hui Zhang
Shanghai Research Center for Theoretical Nuclear Physics NSFC and Fudan University 200438 Shanghai China
11 shared publications - Zhen Zhang
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
11 shared publications - Fan Xia
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
10 shared publications - Ji Zhu
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
10 shared publications Lijun Shen
Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China
9 shared publications
Latest Publications
- Open Access
Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
Introduction Mucosal melanoma (MM) carries a high risk of postoperative relapse and poorer survival than cutaneous disease. Prospective data from China support adjuvant temozolomide–cisplatin (TMZ/DDP) in resected MM, while radiotherapy (RT) may augment antitumour immunity and synergise with programmed death 1 (PD-1) inhibitor. We therefore designed an adjuvant regimen combining short-course RT (SCRT) with chemotherapy and PD-1 inhibitor after curative-intent resection. Methods and analysis This investigator-initiated, single-arm, prospective, phase II study at Fudan University Shanghai Cancer Centre enrols adults (≥18 years) with histologically confirmed MM after R0/R1 resection, Eastern Cooperative Oncology Group (ECOG) performance status 0–1 and M0 disease. Patients receive six 3-week cycles of systemic therapy: pucotenlimab 200 mg IV on day 1; TMZ 200 mg/m² orally on days 1–5 and DDP 25 mg/m² IV on days 1–3. (SCRT; 25 Gy in five fractions) is delivered after the first two cycles of systemic therapy, followed by four additional cycles of systemic therapy without RT. The primary endpoint is 1-year recurrence-free survival (RFS). Secondary endpoints include locoregional RFS, distant metastasis-free survival, overall survival and safety (CTCAE V.5.0). The planned sample size is 47 (44 evaluable), providing 80% power (one-sided α of 0.10) to detect an improvement in 1-year RFS from 55% to 70%. Time-to-event endpoints will be estimated using Kaplan–Meier methods with 95% CIs. Ethics and dissemination The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (approval number: 2407300-5), and all participants will provide written informed consent. Findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial registration number ChiCTR2400093001.
Open AccessAdjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
Introduction Mucosal melanoma (MM) carries a high risk of postoperative relapse and poorer survival than cutaneous disease. Prospective data from China support adjuvant temozolomide–cisplatin (TMZ/DDP) in resected MM, while radiotherapy (RT) may augment antitumour immunity and synergise with programmed death 1 (PD-1) inhibitor. We therefore designed an adjuvant regimen combining short-course RT (SCRT) with chemotherapy and PD-1 inhibitor after curative-intent resection. Methods and analysis This investigator-initiated, single-arm, prospective, phase II study at Fudan University Shanghai Cancer Centre enrols adults (≥18 years) with histologically confirmed MM after R0/R1 resection, Eastern Cooperative Oncology Group (ECOG) performance status 0–1 and M0 disease. Patients receive six 3-week cycles of systemic therapy: pucotenlimab 200 mg IV on day 1; TMZ 200 mg/m² orally on days 1–5 and DDP 25 mg/m² IV on days 1–3. (SCRT; 25 Gy in five fractions) is delivered after the first two cycles of systemic therapy, followed by four additional cycles of systemic therapy without RT. The primary endpoint is 1-year recurrence-free survival (RFS). Secondary endpoints include locoregional RFS, distant metastasis-free survival, overall survival and safety (CTCAE V.5.0). The planned sample size is 47 (44 evaluable), providing 80% power (one-sided α of 0.10) to detect an improvement in 1-year RFS from 55% to 70%. Time-to-event endpoints will be estimated using Kaplan–Meier methods with 95% CIs. Ethics and dissemination The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (approval number: 2407300-5), and all participants will provide written informed consent. Findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial registration number ChiCTR2400093001.
- Open Access
- 1 March 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (3) , 204
Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers
Background: Prediction models for lung metastasis in rectal cancer are limited, and gene mutations have not been incorporated. As genetic testing becomes more common in routine clinical practice, including RAS/BRAF mutation status in lung metastasis risk prediction models may enhance their clinical relevance. This study aimed to identify gene mutations and clinicopathological factors associated with lung metastasis in locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). Methods: A total of 311 consecutive LARC patients who underwent genetic testing and received nCRT followed by tumor curative resection between April 2014 and August 2023 were retrospectively analyzed. The diagnosis of lung metastasis mainly relied on chest computed tomography (CT) findings indicative of metastatic lesions. Predictors were preliminarily selected using Least Absolute Shrinkage and Selection Operator (LASSO) analysis. A prediction model was then developed via multivariate logistic regression and visualized as a nomogram. The model’s performance was evaluated using the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA), and internally validated using the bootstrap validation method. Results: The study cohort included 311 patients with a median age of 55.3 years old (range, 26–76 years old) and 67.5% males. During a median 28-month follow-up period (range, 3–112 months), lung metastasis occurred in 47 patients (15.1%) after surgery. Tumor location, lymphovascular invasion, pathological N stage and RAS mutation were identified as significant factors associated with the risk of lung metastasis. The prediction model had good discrimination, with an area under the receiver operating characteristic curve (AUC) of 0.772. The nomogram’s sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 83.0%, 56.8%, 25.5%, and 94.9%, respectively, at a cutoff value of 142. Conclusions: We identified the risk factors for lung metastasis in LARC patients treated with nCRT and TME and developed a nomogram to facilitate individualized imaging and follow-up strategies. Further studies with larger sample size and external validation are warranted.
- 1 March 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (3) , 204
Open AccessDevelopment and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers
Background: Prediction models for lung metastasis in rectal cancer are limited, and gene mutations have not been incorporated. As genetic testing becomes more common in routine clinical practice, including RAS/BRAF mutation status in lung metastasis risk prediction models may enhance their clinical relevance. This study aimed to identify gene mutations and clinicopathological factors associated with lung metastasis in locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). Methods: A total of 311 consecutive LARC patients who underwent genetic testing and received nCRT followed by tumor curative resection between April 2014 and August 2023 were retrospectively analyzed. The diagnosis of lung metastasis mainly relied on chest computed tomography (CT) findings indicative of metastatic lesions. Predictors were preliminarily selected using Least Absolute Shrinkage and Selection Operator (LASSO) analysis. A prediction model was then developed via multivariate logistic regression and visualized as a nomogram. The model’s performance was evaluated using the receiver operating characteristic (ROC) curve, calibration curves, and decision curve analysis (DCA), and internally validated using the bootstrap validation method. Results: The study cohort included 311 patients with a median age of 55.3 years old (range, 26–76 years old) and 67.5% males. During a median 28-month follow-up period (range, 3–112 months), lung metastasis occurred in 47 patients (15.1%) after surgery. Tumor location, lymphovascular invasion, pathological N stage and RAS mutation were identified as significant factors associated with the risk of lung metastasis. The prediction model had good discrimination, with an area under the receiver operating characteristic curve (AUC) of 0.772. The nomogram’s sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 83.0%, 56.8%, 25.5%, and 94.9%, respectively, at a cutoff value of 142. Conclusions: We identified the risk factors for lung metastasis in LARC patients treated with nCRT and TME and developed a nomogram to facilitate individualized imaging and follow-up strategies. Further studies with larger sample size and external validation are warranted.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Duration of cCR in each individual patient who adopted WW
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Duration of cCR in each individual patient who adopted WW
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Characteristics of Patients Developing Tumor Recurrence
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Characteristics of Patients Developing Tumor Recurrence
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Postoperative complications according to Clavien- Dindo classification
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Postoperative complications according to Clavien- Dindo classification
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Representativeness of Study Participants
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Representativeness of Study Participants
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4976-4984
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Purpose: Organ preservation (OP) can be preferred in low-lying rectal cancer to reduce morbidity from radical surgery. Immunotherapy-based total neoadjuvant therapy (iTNT) showed remarkable tumor regression and facilitated OP in locally advanced rectal cancer. This study evaluated the efficacy and safety of iTNT, comprising short-course radiotherapy followed by CAPOX and toripalimab, in enabling OP for early low rectal cancer. Patients and Methods: TORCH-E was a multicenter, single-arm phase II trial enrolling patients with T2–3bN0 rectal adenocarcinoma ≤5 cm from the anal verge. Patients received short-course radiotherapy (25 Gy/5 Fx) followed by four cycles of CAPOX plus toripalimab. Good responders were eligible for watch-and-wait (WW) or local excision (LE), and total mesorectal excision was recommended for poor responders or those with high-risk features after LE. The primary endpoint was complete response (CR), including clinical CR with WW and pathologic CR. Secondary endpoints included OP rate, adverse effects, and quality of life. Results: From December 2022 to March 2024, 33 patients were enrolled, with 75.8% staged as T3. After iTNT, 16 patients achieved clinical CR and adopted WW. Pathologic CR was observed in eight of eight LE and five of nine patients who underwent total mesorectal excision. The most common grade 3 to 4 adverse event was thrombocytopenia (27.3%). After a median follow-up of 24.1 months, four local regrowths and one metastatic recurrence occurred. The total CR rate was 72.7%, and the OP rate was 60.6%. Conclusions: As an exploratory trial, TORCH-E demonstrated a promising iTNT approach achieving a high CR rate, enabling OP through WW and selective LE in early low rectal cancer, warranting subsequent randomized validation.
- 30 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4976-4984
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
Purpose: Organ preservation (OP) can be preferred in low-lying rectal cancer to reduce morbidity from radical surgery. Immunotherapy-based total neoadjuvant therapy (iTNT) showed remarkable tumor regression and facilitated OP in locally advanced rectal cancer. This study evaluated the efficacy and safety of iTNT, comprising short-course radiotherapy followed by CAPOX and toripalimab, in enabling OP for early low rectal cancer. Patients and Methods: TORCH-E was a multicenter, single-arm phase II trial enrolling patients with T2–3bN0 rectal adenocarcinoma ≤5 cm from the anal verge. Patients received short-course radiotherapy (25 Gy/5 Fx) followed by four cycles of CAPOX plus toripalimab. Good responders were eligible for watch-and-wait (WW) or local excision (LE), and total mesorectal excision was recommended for poor responders or those with high-risk features after LE. The primary endpoint was complete response (CR), including clinical CR with WW and pathologic CR. Secondary endpoints included OP rate, adverse effects, and quality of life. Results: From December 2022 to March 2024, 33 patients were enrolled, with 75.8% staged as T3. After iTNT, 16 patients achieved clinical CR and adopted WW. Pathologic CR was observed in eight of eight LE and five of nine patients who underwent total mesorectal excision. The most common grade 3 to 4 adverse event was thrombocytopenia (27.3%). After a median follow-up of 24.1 months, four local regrowths and one metastatic recurrence occurred. The total CR rate was 72.7%, and the OP rate was 60.6%. Conclusions: As an exploratory trial, TORCH-E demonstrated a promising iTNT approach achieving a high CR rate, enabling OP through WW and selective LE in early low rectal cancer, warranting subsequent randomized validation.
- Open Access
The predictive value of LGR for distant metastasis-free survival in locally advanced rectal cancer patients